Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
On Wednesday, Cantor Fitzgerald reaffirmed its Overweight rating and $13.00 price target for Vanda Pharmaceuticals (NASDAQ:VNDA), emphasizing the company’s progress and future prospects despite previous challenges. Currently trading at $3.94, significantly below its 52-week high of $6.75, InvestingPro analysis suggests the stock is undervalued. The firm acknowledged Vanda’s past difficulties with the FDA, strategic missteps, and unfavorable patent rulings but noted significant improvements in the last year.
The investment firm highlighted Vanda’s refocused efforts on its psychiatric products, Fanapt and Bysanti, and the expansion of its pipeline with multiple new NDA/BLA submissions. These developments are expected to drive the company’s growth in the coming years, particularly with the anticipated launch of Fanapt for bipolar 1 disorder and the progression of next-generation product Bysanti, which has a PDUFA date set for February 2026. The company’s impressive gross profit margin of 94.34% and strong current ratio of 3.93 support its growth strategy.
Cantor Fitzgerald pointed out the potential for Vanda’s revenue stream to grow in the second half of 2025, bolstered by these product launches and the upcoming readout of an encore indication in Major Depressive Disorder (MDD) next year. The firm also referenced Vanda’s earlier announcement of long-term financial guidance, projecting $1 billion in total revenues by 2030, with $750 million expected to come from its CNS franchise.
The analyst’s comments underscored the perceived gap between Vanda’s current valuation and its future revenue potential, suggesting a significant opportunity for growth. The firm’s continued support for Vanda’s stock reflects confidence in the company’s strategy and its ability to overcome past hurdles.
In other recent news, Vanda Pharmaceuticals reported its financial results for the first quarter of 2025, revealing a revenue of $50 million, which was below the analyst forecast of $61.02 million. The company also recorded a net loss of $29.5 million, a significant increase from the $4.1 million loss reported in the same quarter the previous year. Despite this, product revenues for Fanapt and HETLIOZ showed growth, with Fanapt revenue increasing by 14% to $23.5 million and HETLIOZ revenue rising by 4% to $20.9 million. However, PONVORY’s revenue declined by 18% to $5.6 million.
For the full year 2025, Vanda Pharmaceuticals has provided a revenue guidance range of $210 million to $250 million, with expectations of having six products commercially available by 2026. Analysts from firms such as Jefferies and Cantor Fitzgerald have been inquiring about the company’s pipeline and market strategies, indicating continued interest in Vanda’s future developments. The company faces challenges such as market competition and regulatory hurdles, which could impact its growth trajectory. Despite these challenges, Vanda Pharmaceuticals is focusing on expanding its product offerings and market presence, as highlighted by its recent strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.